Insight Molecular Diagnostics (IMDX) Stock Forecast: StockMap's 2-Week Call

IMDX stock forecast: StockMap's model calls Insight Molecular Diagnostics Strong Underperform for the two weeks after the Nov 19 close: it expects IMDX to trail the growth index. It is a call on the gap, not a price target. Right in 5 of 6 two-week windows on IMDX since Aug 21; by chance, a call on the same dates was right 59% of the time.

Insight Molecular Diagnostics last closed at $1.66, +4.40% on the session.

Against the IVW growth benchmark the position is +6.73% over the forecast window.

Insight Molecular Diagnostics' market cap is $54.38M as of November 19, 2026.

Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -51 (behind).

Where IMDX sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 0 bullish and 15 bearish.

Agreement across those insights is 100%.

46 daily calls for IMDX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Insight Molecular Diagnostics in the 98th percentile on return on equity, where 100 is best.

Insight Molecular Diagnostics is classified under Health Care / Biotechnology.

StockMap tracks Insight Molecular Diagnostics as the 303rd largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.

On that composite Insight Molecular Diagnostics ranks 352nd of 394 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Insight Molecular Diagnostics (IMDX) — StockMap 2-week forecast & tracked accuracy